Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 30;18(6):2099210.
doi: 10.1080/21645515.2022.2099210. Epub 2022 Jul 26.

Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China

Tao-Hsin Tung  1 , Xiao-Qing Lin  2 , Yan Chen  2 , Mei-Xian Zhang  1 , Jian-Sheng Zhu  2
Affiliations

Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China

Tao-Hsin Tung et al. Hum Vaccin Immunother. .

Abstract

This study was conducted to ascertain whether people in China would be willing to pay for an inactivated COVID-19 vaccine booster dose. An online survey estimating participants' willingness to pay (WTP) for a booster dose of COVID-19 vaccine was conducted in Taizhou, China. The participants received ane-mail or e-poster on WeChat. A total of 1576 subjects participated the survey. A total of 66.4% (1046/1576) of the respondents were willing to pay for a booster dose of COVID-19 vaccine for themselves. Using binary logistic regression analysis, the following factors were significantly related to a WTP for a booster dose of COVID-19 vaccine: 1) confidence in the safety of the COVID-19 vaccines (high vs. low, OR: 4.30, 95%CI: 1.61-11.43), 2) confidence in the preventive effectiveness of the COVID-19 vaccines against SARS-CoV-2 virus (moderate vs. little, OR: 1.76, 95%CI: 1.30-2.38; great vs. little, OR: 2.244, 95%CI: 1.62-3.12), and 3) COVID-19 vaccine hesitancy (unhesitant vs. very unhesitant, OR: 0.67, 95%CI: 0.45-1.02; hesitant vs. very unhesitant, OR: 0.29, 95%CI: 0.19-0.44; very hesitant vs. very unhesitant, OR: 0.09, 95%CI: 0.03-0.27). This study revealed that a moderate proportion of participants responded that they would be willing to pay for a booster dose of COVID-19 vaccine. These findings suggest the importance of a detailed assessment and a health education plan that better understands the population's risk perception as well as the potential health risks in China.

Keywords: COVID-19; China; booster dose; willingness-to-pay.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Distribution of willingness to pay in price for the booster dose of COVID-19 vaccine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Zhang M-X, Zhang T-T, Shi G-F, Cheng F-M, Zheng Y-M, Tung T-H, Chen H-X.. Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China. Expert Rev Vaccines. 2021;20:1–7. doi:10.1080/14760584.2021.1925112. - DOI - PMC - PubMed
    1. Habas K, Nganwuchu C, Shahzad F, Gopalan R, Haque M, Rahman S, Majumder AA, Nasim T. Resolution of coronavirus disease 2019 (COVID-19). Expert Rev Anti Infect Ther. 2020;18:1201–1211. doi:10.1080/14787210.2020.1797487. - DOI - PubMed
    1. Guidry JPD, Laestadius LI, Vraga EK, Miller CA, Perrin PB, Burton CW, Ryan M, Fuemmeler BF, Carlyle KE. Willingness to get the COVID-19 vaccine with and without emergency use authorization. Am J Infect Control. 2021;49:137–142. doi:10.1016/j.ajic.2020.11.018. - DOI - PMC - PubMed
    1. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Sci. 2020;369:77–81. doi:10.1126/science.abc1932. - DOI - PMC - PubMed
    1. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182:713–21 e9. doi:10.1016/j.cell.2020.06.008. - DOI - PMC - PubMed

Substances

Supplementary concepts